AllDocs -> cancers

101 V OLUME 3, N UMBER 2 ¦ M ARCH /A PRIL 2005 www.SupportiveOncology.net J Support Oncol 2005;3:101–110 © 2005 Elsevier Inc. All rights reserved. R E V I E W A Multidisciplinary Approach to Gastrointestinal Bleeding in Cancer Patients John J.Imbesi,MD,and Robert C.Kurtz,MD Abstract Gastrointestinal bleeding remains one of the most challenging areas in medicine today,especially in the patient with cancer .New tech- niques and technology have added much to the diagnosis and manage- ment of gastrointestinal bleeding.Although gastroenterologists remain at the center of the evaluation of these patients, the incorporation of new techniques has meant that interventional radiologists and nuclear medicine specialists often have important roles in assessing and treat- ...

• BRIEF REPORTS • Raman spectra of single cell from gastrointestinal cancer patients Xun-Ling Yan, Rui-Xin Dong, Lei Zhang, Xue-Jun Zhang, Zong-Wang Zhang ELSEVIER PO Box 2345, Beijing 100023, China World J Gastroenterol 2005;11(21):3290-3292 www.wjgnet.com World Journal of Gastroenterology ISSN 1007-9327 wjg@wjgnet.com © 2005 The WJG Press and Elsevier Inc. All rights reserved. Xun-Ling Yan, Rui-Xin Dong, School of Physics Science and Information Engineering, Liaocheng University, Liaocheng 252059, Shandong Province, China Lei Zhang, Xue-Jun Zhang, Zong-Wang Zhang,Surgery of Liaocheng People’s Hospital, Liaocheng 250059, Shandong Province, China Supported by the National Natural Science Foundation of China, No. 60471049 and the Natural Science Foundation of Shandong Province of China, No. Y2004G09 Correspondence to: Xun-Ling Yan, School ...

TNFerade TM Combined with Chemoradiation in Gastrointestinal Cancer : Phase I/II Studies in Unresectable Locally Advanced Pancreatic and Resectable Esophageal Cancer Neil Senzer, MD Scientific Director Mary Crowley Medical Research Center US Oncology, Dallas, TX On behalf of the TNFerade TM Investigators Page 2 What is TNFerade TM ? • TNFerade is a second-generation (E1-, partial E3-, and E4-deleted) adenovector carrying the transgene encoding for TNF- a • A radiation-inducible promoter (Egr-1) is incorporated in the construct to optimize spatial and temporal gene expression following ionizing radiation Page 3 Rationale of TNFerade and Radiation Therapy Transcriptional targeting using a radiation- inducible, radio-sensitizing ...

Orthotopic transplantation model of human gastrointestinal cancer and detection of micrometastases Jun Hui Cui 1 , Uwe Krueger 2 , Doris Henne-Bruns 2 , Bernd Kremer 2 and Holger Kalthoff 2 Subject headings mice, nude; gastrointestinal neoplasms/ pathology; neoplasm seeding; neoplasm metastasis Cui JH, Krueger U, Henne-Bruns D, Kremer B, Kalthoff H. Orthotopic transplantation model of human gastrointestinal cancer and detection of micrometastases. World J Gastroenterol , 2001;7(3):381-386 Abstract AIM To establish a relevant animal model of human gastrointestinal cancer , which can be used for repetitive investigations, so as to improve our understanding and management of carcinogenesis and cancer metastasis. METHODS Intact tissues of human colorectal and pancreatic cancers ...

TREATMENT-INDUCED GASTROINTESTINAL TOXICITY IN PATIENTS WITH CANCER KEYNOTE ADDRESS LINDA S. ELTING, DRPH DOROTHY M. K. KEEFE, MBBS, MD, FRACP STEPHEN T. SONIS, DMD, DMSC Page 2 2 Faculty Faculty Linda S. Elting, DrPH Associate Professor of Biostatistics Chief of Health Services Research University of Texas MD Anderson Cancer Center Dorothy M. K. Keefe, MBBS, MD, FRACP Senior Lecturer in Oncological Medicine Department of Medicine University of Adelaide RAH Cancer Centre Royal Adelaide Hospital Stephen T. Sonis, DMD, DMSc Professor of Oral Medicine Harvard School of Dental Medicine Divisions of Oral Medicine Brigham & Women’s Hospital and the Dana Farber Cancer Institute © M A S CC 2004 Page ...

Connections between single-cell biomechanics and human disease states: gastrointestinal cancer and malaria S. Suresh a,b, * , J. Spatz c , J.P. Mills a , A. Micoulet c , M. Dao a , C.T. Lim d , M. Beil e , T. Seufferlein e a Department of Materials Science and Engineering, and Division of Bioengineering, Massachusetts Institute of Technology, Room 8-309, 77 Massachusetts Ave., Cambridge, MA 02139-4307, USA b Division of Biological Engineering and Affiliated Faculty of the Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA 02139-4307, USA c Institute for Physical Chemistry, Biophysical Chemistry, University of Heidelberg, INF 253, 69120Heidelberg, Germany d Division of Bioengineering and Department of Mechanical ...

Fox Chase Cancer Center 2003 Scientific Report 1 Elin R. Sigurdson, M.D., Ph.D., Senior Member Burton L. Eisenberg,* a M.D., F.A.C.S., Senior Member John P. Hoffman, M.D., F.A.C.S., Senior Member James C. Watson, M.D., Associate Member Lydia Giles, R.N., Study Coordinator Cathy O’Hare, Senior Medical Secretary Gastrointestinal (GI) cancer surgeons provide multidisciplinary care for patients with malignant and benign tumors arising in the GI tract from the esophagus to the anus, as well as surgical evaluation and interven- tion to FCCC patients who develop non- cancer related pathology of these sites. Complete tumor resection continues to be the mainstay of optimal treatment of all localized gastrointestinal cancers, with general principles of oncologic surgery advocating removal of the primary lesion with adequate margins, including the ...

Fox Chase Cancer Center 2003 Scientific Report 1 Gastrointestinal Cancer Therapeutics. Meropol, Sigurdson, in collaboration with Allard, a Blanchard, § Cheng, § S. Cohen, § Eisenberg, § Engstrom, § Freedman, § Gallo, § Godwin, § Goldberg, § Hoffman, § Konski, § Lewis, § Rogatko, § Scott, § Szarka, § von Mehren, § Watson, § Weiner § Given the relative resistance of GI cancers to standard chemotherapeutic agents, a major emphasis of the GI cancer program at Fox Chase involves development of novel systemic approaches. Overall goals of the program are to: 1) develop treatments with ...

General Practitioner in Oncology Self-directed Learning Program GASTROINTESTINAL CANCER MODULE Page 2 Anal Cancer Case Scenario 1 A 65-year-old woman presents to her family physician with a complaint of bleeding from a hemorrhoid. On rectal examination, a 2 cm mass is detected. She is referred to a surgeon, and undergoes biopsy, which reveals a moderately differentiated squamous cell carcinoma. 1. What staging working would you order and why? 2. What are some of the risk factors for anal cancer ? 3. In what age group is anal cancer more common in men than women? 4. In what age group is anal cancer more common in women than men? The patient undergoes chest x-ray, CBC, electrolytes, liver function tests, and a CT scan of the abdomen and pelvis. Chest x-ray is normal. CBC, electrolytes, urea, Creatinine, liver function ...

Abstract. Thymidine phosphorylase (TP) and dihydro- pyrimidine dehydrogenase (DPD) are considered to be key enzymes affecting the prognosis for patients with advanced gastrointestinal cancer . Preoperative examination of TP and DPD expression levels and assessment of these enzymes in inoperable cancer patients may contribute to successful treatment. We tried to prove the correlation of TP and DPD expression in preoperative specimens by endoscopy and in surgical specimens. The present study was designed to quantify TP and DPD levels by enzyme-linked immunosorbent assay (ELISA) in tumor tissue obtained from 30 gastrointestinal cancer patients by preoperative endoscopy and surgery, including 15 gastric and 15 colorectal cancers. Successful cases as those in which cancer cells were demonstrated histologically in preoperative specimens by endoscopy were 12 (success rate: 80%) in gastric cancer ...

Novartis International AG Novartis Communications CH-4002 Basel Switzerland Tel + 41 61 324 2200 Fax + 41 61 324 3300 Internet address: http://www.novartis.com *In the US: Gleevec ® (imatinib mesylate) 1/2 MEDIA RELEASE • COMMUNIQUE AUX MEDIAS • MEDIENMITTEILUNG Glivec ® approved in Japan for treatment of life-threatening gastrointestinal cancer Basel, Switzerland, 17 July 2003 – Novartis announced today that health authorities in Japan have approved Glivec ® (imatinib)* for the treatment of patients with KIT (CD117) positive gastrointestinal stromal tumors (GISTs), a life-threatening cancer . Historically, GISTs have been very difficult to treat due to their resistance to treatment with available chemotherapy and radiation therapy. Previously, surgery ...

Cambridge-Munich Upper Gastrointestinal Cancer Workshop Trinity College Cambridge March 28 th to 30 th 2004 Preliminary Programme Sunday 28 th March Afternoon - Tour of colleges Evening - Trinity College Drinks reception Guest lecture: Molecular imaging Professor Kevin Brindle, Biochemistry Department, Cambridge Informal buffet supper Page 2 Monday 29 th March Introduction and aims of the workshop : Carlos Caldas and Heinz Hoefler Morning session 1 – Genetic susceptibility to upper GI cancers Caldas (Oncology, Cambridge) Hereditary diffuse gastric cancer Keller/Vogelsang (Pathology, Munich) Familial gastric cancer Pharoah (Oncology, Cambridge) Low penetrance susceptibility genes - Stomach Oesophageal Cancer Study ...

PRACTICAL GASTROENTEROLOGY • MARCH 2004 52 INTRODUCTION N umerous studies have been done to examine what role diet plays in protection against gastrointesti- nal cancers. In order to make the best suggestions for physicians and patients, a careful review of the data is provided. The area of diet and cancer prevention is evolving, and, at the current time, much of the data is epidemiological or from basic science animal models. Some of the data is from humans in retrospective for- mat, prospective cohorts, and a few randomized placebo controlled studies. In order to understand the evolution and how suggestions are being formed, it is essential to review all of the studies available as each type has value. This article provides a review of the best data available and makes suggestions based on the literature at hand in regards to nutrients, diet, and cancer preven- ...

Long-acting Repeatable (Lar) Octreotide for Clinical Management of Gastrointestinal Cancer a report by Alessandra Mosca Managing Director, Department of Clinical Oncology, San Luigi Hospital, Orbassano, Italy on behalf of Novartis Pharma AG e-mail: ale.mos@libero.it Page 2 O C T R E O T I D E L A R I N G A S T R O I N T E S T I N A L T U M O U R S 2 Abstract Octreotide represents a novel approach to the treatment of various endocrinological and oncological disorders. Its effects are mediated through its interaction with the somatostatin receptor subtype 2, and to a lesser extent subtypes 5 and 3, and subsequent effects on hormone secretion. A long-acting repeatable (LAR) formulation of octreotide is now available. It is administered by intramuscular injection every 4 weeks. Results to date suggest that octreotide LAR appears ...

Abstract. WNT2 gene on human chromosome 7q31 is a paralog of the WNT2B gene on human chromosome 1p13. Rat Wnt2 gene was identified within rat genome draft sequence AC095247.4. Human WNT2 showed 96.4% total-amino-acid identity with rat Wnt2, 96.1% with mouse Wnt2, 68.6% with zebrafish wnt2, and 67.8% with fugu wnt2. WNT2 is an evolutionarily conserved secreted-type glycoprotein belonging to the WNT family. WNT2 mRNA is expressed in human fetal lung and placenta, but almost undetectable in normal gastro- intestinal tract. WNT2 mRNA is frequently up-regulated in human gastric cancer due to tumor-stromal interaction, and WNT2 gene is rarely amplified in human gastric cancer . WNT2 mRNA is also frequently up-regulated in colorectal polyps, primary colorectal cancer of stage A-C, and also in liver metastasis from colorectal cancer . Putative biding sites for estrogen receptor, GATA-1, ...

March 2003, Vol. 32 No. 2 219 Peritoneal Carcinomatosis from GI Cancer —D G Jayne * Senior Lecturer & Honorary Consultant Surgeon Academic Surgical Unit St. James’s University Hospital & University of Leeds, UK (formerly Colorectal Fellow, Singapore General Hospital, Singapore) Address for Reprints: Dr David Jayne, Academic Surgical Unit, Level 8, Clinical Sciences Building, St. James’s University Hospital, Beckett Street, Leeds LS9 7TF, United Kingdom. E-mail: meddgj@leeds.ac.uk The Molecular Biology of Peritoneal Carcinomatosis from Gastrointestinal Cancer D G Jayne,* MBBCh, MD, FRCS Abstract Introduction: Peritoneal carcinomatosis is a frequent form of disease progression in gastrointestinal cancer , and all too often is a preterminal event with a median survival of only 6 months. Despite the introduction of aggressive surgical and ...

JOURNAL OF PATHOLOGY J. Pathol. 187 : 223–228 (1999) SYNTHESIS OF BASEMENT MEMBRANE BY GASTROINTESTINAL CANCER CELL LINES TAKUMI AKASHI 1 *, TIZUKO MIYAGI 1 , NOBORU ANDO 1 , YOSHIMI SUZUKI 1 , TETSUO NEMOTO 1 , YOSHINOBU EISHI 1 , KYOICHI NAKAMURA 1 , TAKUJI SHIRASAWA 2 , NATSUMI OSA 3 , NOBORU TANAKA 3 AND ROBERT E. BURGESON 4 1 Department of Pathology, Tokyo Medical and Dental University, Tokyo, Japan 2 Department of Molecular Pathology, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan 3 PCL Japan, Tokyo, Japan 4 Cutaneous Biology Center, Harvard Medical School, Charleston, MA, U.S.A. SUMMARY Gastrointestinal adenocarcinoma-derived cell ...

GASTROINTESTINAL CANCER Prof. Dr. M. Peeters Dept of Gastroenterology/Oncology University Hospital Ghent On this thirty-ninth annual meeting of the American Society of Clinical Oncology in Chicago, Illinois, 524 abstracts on Gastrointestinal Cancer (GI) were published in the abstract book. Approximately 170 GI cancer papers were, either orally or as poster, presented at the meeting itself. Not only was the quantity excellent. Also the quality was outstanding this year. Mature data from several large, randomized trials became available and were discussed. For example, convincing results on the role of novel agents in the treatment of metastatic colorectal cancer were presented. The conclusions will certainly influence our clinical practice in the near future. It was absolutely necessary to make a selection in the presented material for this paper. We decided ...

Fox Chase Cancer Center 2002 Scientific Report Gastrointestinal Cancer Therapeutics. Meropol, Sigurdson, in collaboration with Cheng, § S. Cohen, § Eisenberg, § Engstrom, § Freedman, § Goldberg, § Hoffman, § Konski, § Lewis, § Scott, § Szarka, § von Mehren, § Weiner, § Allard, a Gallo, § Godwin, § Raftogianis, § Rogatko, § Watson § Given the relative resistance of GI cancers to standard chemotherapeutic agents, a major emphasis of the GI cancer program at Fox Chase involves development of novel systemic approaches. Overall goals of the program are to: 1) develop treatments with improved ...

Summer, 2002 GWCCS Cancer Support Group & Internet Resource Guide Page 1 www.gwccs.org Greater Washington Coalition for Cancer Survivors (202) 364-6422 Colorectal & Gastrointestinal Cancer Support Groups SPONSOR GROUP / DESCRIPTION DAY & TIME LOCATION CONTACT & PHONE STATE Anne Arundel Medical Center Colorectal Cancer Support Group 2 nd Tuesday 7:00 PM AAMC Sajak Pavilion - 2001 Medical Parkway Annapolis, MD (443) 481-5369 MD Colorectal Cancer Network (CCNet) SemiColon - Two groups; one for survivors and one for caregivers 2 nd and 4 th Thursday 7:30-8:30 PM Holy Cross Hospital Audi- torium Forest Glen Road Silver Spring, MD Priscilla Savary (301) 879-1500 MD Colorectal Cancer ...

Fox Chase Cancer Center 2001 Scientific Report Gastrointestinal Cancer Therapeutics. Meropol, Sigurdson, Cohen, in collaboration with Cheng, § Eisenberg, § Engstrom, § Freedman, § Goldberg, § Hoffman, § Lewis, § Scott, § Szarka, § von Mehren, § Weiner, § Allard, a Gallo, § Godwin, § Raftogianis, § Rogatko § Given the relative resistance of GI cancers to standard chemotherapeutic agents, a major emphasis of the GI cancer program at Fox Chase involves development of novel systemic approaches. Overall goals of the program are to: 1) develop treatments with improved target selectivity, and 2) identify tumor characteristics that will permit ...

cancer 1581 Wharton Department of Statistics Profiting from Data Mining Bob Stine Department of Statistics The Wharton School, Univ of Pennsylvania April 5, 2002 www-stat.wharton.upenn.edu/~bob Wharton Department of Statistics 2 Overview Critical stages of data mining process Choosing the right data, people, and problems Modeling Validation Automated modeling Feature creation and selection Exploiting expert knowledge, “insights” Applications Little detail – Biomedical: finding predictive risk factors More detail – Financial: predicting returns on the market Lots of detail – Credit: anticipating the onset of bankruptcy Wharton Department of Statistics 3 Predicting Health Risk Who is at risk for a disease? ...

1 Questions for Gastrointestinal Drugs Advisory Committee Chemoprevention of Sporadic Colorectal Cancer (CRC) March 19, 2002 1) For individuals who are able and willing to undergo colonoscopic screening or surveillance, is either partial and/or complete suppression of colorectal adenomatous polyps a clinically meaningful benefit? Why or why not? If adenomatous polyp suppression is not a clinically meaningful benefit, what additional information would be needed to demonstrate that partial or complete suppression of polyps is of clinical benefit in such individuals? 2) A chemoprotective agent (CPA) that suppresses polyp growth may become resistant to drug effects. Additionally, it may preferentially allow small, invasive lesions to go undetected on colonoscopy while large, indolent lesions are identified and removed. If polyp suppression is used as an endpoint in clinical trials of a CPA: ...

THE PHASE 2 AND 3 GASTROINTESTINAL CANCER PIPELINE Information for this chart was gathered from the Pharmaceutical Research and Manufacturers of America, corporate Web sites, meeting abstracts, and the databases of H EM /O NC T ODAY . The publisher or editors do not assume responsibility for any errors or omissions. Compiled by Kristine Welsh, Associate Editor Generic Name Product Name Company Indication Phase Anti-gastrin therapeutic vaccine Not yet available Aphton Corporation Colorectal cancer ; pancreatic cancer ; stomach Phase 2/3 cancer ; esophageal cancer ; liver cancer Anti-idiotype antibody TriGem Titan Pharmaceuticals Colorectal cancer Phase 2 Anti-VEGF Not yet available Genetech Colorectal cancer Phase 3 Autologous vaccine OncoVAXCL ...

182 Medical Science Division Gastrointestinal Cancer Therapeutics. Meropol, Sigurdson, Cohen, Cheng, § Eisenberg, § Engstrom, § Freedman, § Goldberg, § Hoffman, § Lewis, § Pinover, § Szarka, § von Mehren, § Weiner, § Cohen a Given the relative resistance of GI cancers to standard chemotherapeutic agents, a major emphasis of the GI cancer program at Fox Chase involves development of novel sys- temic approaches. Clinical trials include thera- pies based upon molecular targets, as well as traditional cytotoxics with preclinical evidence of improved antitumor activity or selectivity. Pharmacologic modeling of new agents is rou- tinely performed (see GALLO report for more ...

Abstract: Significant benefits have been gained with pre or peri-operative nutritional support in surgical patients with malnutrition. Recent studies have also shown that some enteral formulas including certain nutrients like glutamine could provide more benefit than the standard formulas. In this prospective-randomized study, the effects of perioperative oral supplement with enteral formulas containing glutamine in comparison with a standard enteral formula in patients who were operated on for GI malignancies were examined. Thirty-two patients were divided into two groups: the study group was given oral supplement with an elemental diet (Alitraq ® ) for 7 days preoperatively and 10 days postoperatively as 30-35% of total daily requirement (standard hospital diet: 65- 70%), while the control group received a polymeric formula (Ensure ® ) as the ...

180 Medical Science Division GASTROINTESTINAL CANCER PROGRAM Neal J. Meropol, M.D., Member, Director, Gastrointestinal Cancer Program, Director, Gastrointestinal Tumor Risk Assessment Program Elin R. Sigurdson, M.D., Ph.D., Member, Surgical Co-Director, Gastrointestinal Cancer Program Jonathan D. Cheng, M.D., Research Fellow (now Assistant Member, Medical Science) Alida Schleyer, R.N., B.S.N., Project Coordinator Sandy Corbett, B.S., Project Assistant Joni James,* M.P.H., Health Educator Susan Mazzoni, M.P.H., Health Educator Monica Davey, R.N., B.S.N., M.B.A., Clinical Research Coordinator Susan McLaughlin, R.N., Clinical Research Coordinator Mary Beard, B.A., C.T.R., Clinical Research Associate Carolyn Rosado, B.S., Clinical Research Associate Karen Schmidt,* C.C.R.A., Clinical Research Associate Sherry ...

gastrointestinal cancer 1146 JOINT AUGIS/ALS POSITION STATEMENT ON LAPAROSCOPIC UPPER GASTROINTESTINAL CANCER SURGERY Laparoscopic cancer surgery has developed rapidly in the last few years, and techniques continue to evolve. Although most published series of resectional surgery have focussed on operations performed for relatively early stage tumours, it is important that more extensive laparoscopic procedures which include a radical lymphadenectomy, are carried out safely and with the same regard to oncological principles that have been established at “open” surgery. The extent to which encouraging initial results can be applied to the generality of UK patients where more advanced tumours and obesity play important roles, merits careful evaluation in oesophago-gastric and HPB cancer by upper gastrointestinal surgeons. Meticulous prospective audit of results is essential to ensure that complications ...